ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0534 • ACR Convergence 2024

    Patient Reported Outcomes and Disease Activity from a Phase 1 Double-Blind Randomized Clinical Trial of Allogeneic Mesenchymal Stem Cells in Early Rheumatoid Arthritis

    Alexandre Matar1, Maya Breitman2, Tracey Bonfield3, Maricela Haghiac4, Jane Reese3, Emma Barnboym5, Steven Lewis6, Hillard Lazarus7 and Nora Singer8, 1MetroHealth, Westlake, OH, 2MetroHealth Medical Center,Case Western Reserve University School of Medicine, Cleveland, OH, 3Case Western Reserve University, Cleveland, OH, 4Metrohealth Medical Center, Cleveland, OH, 5The MetroHealth System, Cleveland, OH, 6Case Western University, MetroHealth, Cleveland, OH, 7Case Western Reserve University/University Hospitals, Cleveland, OH, 8MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH

    Background/Purpose: Mesenchymal stem (stromal) cells (MSCs) constitute an emerging therapeutic strategy for several human diseases. Small non-randomized studies have shown that MSCs may be a…
  • Abstract Number: 0563 • ACR Convergence 2024

    Clinical Features of Patients with SpA, with or Without IBD: Results from the METEOR Cohort

    Manouk de hOoge1, Pedro M. Machado2, Sytske Anne Bergstra3, Maxime Dougados4, Clementina López Medina5, Victoria Navarro Compán6, Diego Benavent7, Denis Poddubnyy8, Levent kilic9, Philippe Carron10, Dirk Elewaut11, Filip Van den Bosch12 and Gaelle Varkas12, 1Dept. of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium, 2Department of Rheumatology, University College London Hospitals NHS Foundation Trust; and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust; and Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, 3LUMC, Leiden, Netherlands, 4Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, 5Reina Sofia University Hospital, Cordoba, Spain, 6La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, 7Rheumatology Department, Hospital Universitari de Bellvitge, Barcelona, Spain, CAMBRILS, Spain, 8Charite-Universitatsmedizin Berlin, Berlin, Germany, 9Dept. of Rheumatology, Hacettepe University, Ankara, Turkey, Ankara, Turkey, 10UZ Gent, Gent, Belgium, 11Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, 12Ghent University Hospital, Ghent, Belgium

    Background/Purpose: To investigate clinical features of SpA patients with and without IBD, identifying the patient group that would benefit from initiating therapy with efficacy in…
  • Abstract Number: 0554 • ACR Convergence 2024

    Different Prevalence of Intestinal Inflammation in Radiographic and Non-radiographic Axial Spondyloarthritis. Data from EISER Study

    Carolina Merino1, Zulema Plaza2, Jordi Gratacos Masmitja3, Iago Rodríguez-Lago4, Elisa Trujillo5, Ignacio Marin-Jimenez6, Eva Perez Pampin7, Manuel Barreiro8, Vanesa Hernández-Hernández9, Marta Carrillo-Palau10, Maria Luz Garcia Vivar11, Maria Carmen Muñoz12, María Lourdes Ladehesa-Pineda13, Eva Iglesias Flores14, Yago González-Lama15, Marta Arevalo Salaet16, Xabier Calvet17, Ana Gutierrez-Casbas18 and JESUS SANZ SANZ19, and EISER group, 1Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda (Madrid), Spain, 2Fundacion Española de Reumatología, Madrid, Spain, 3University Hospital Parc Taulí, Sabadell, Spain, 4Gastroenterology department. Hospital Universitario Galdakao-Usansolo, Instituto de Investigación Sanitaria Biobizkaia, Galdakao, Bizkaia, Spain, Galdakao, Spain, 5Rheumatology department. Hospital Universitario de Canarias, La Laguna. Tenerife, Spain, 6Gastroenterology department. Hospital Universitario Gregorio Marañón, Madrid, Spain, 7Rheumatology department. Instituto de Investigación Sanitaria de Santiago (IDIS), Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Santiago de Compostela, Spain, 8Gastroenterology department. Hospital Clínico Universitario de Santiago de Compostela Santiago de Compostela, Spain, Santiago de Compostela, Spain, 9Hospital Universitario de Canarias, San Cristobal de La Laguna, Canarias, Spain, 10Gastroenterology department. Hospital Universitario Canarias, La Laguna, Spain., Santa Cruz de Tenerife, Spain, 11Basurto Hospital, Bilbao, Spain, 12Gastroenterology department. Hospital Universitario Basurto Hospital Universitario Basurto. Bilbao. Spain., Bilbao., Spain, 13IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, 14Gastroenterology department. Hospital Reina Sofia, Córdoba, Spain, Cordoba, Spain, 15Servicio de Gastroenterología, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Madrid, Majadahonda, Spain, 16Parc Tauli Hospital Universitari I3PT, Rheumatology, Medicine Department, UAB, Sabadell, Spain, 17Gastroenterology department. Parc Taulí, Hospital Universitari. Institut d’Investigació i Innovació Parc Taulí. Universitat Autònoma de Barcelona. Sabadell, Spain, Sabadell, Spain, 18Gastroenterology department. Hospital General Universitario de Dr. Balmis de Alicante. ISABIAL y CIBERehd, Alicante, Spain, Alicante, Spain, 19Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda, Spain

    Background/Purpose: Axial spondyloarthritis (AxSpA) encompasses both non-radiographic axial spondyloarthritis (nr-AxSpA) and radiographic axial spondyloarthritis (r-AxSpA), also known as ankylosing spondylitis (AS). Although nr-AxSpA is often…
  • Abstract Number: 0547 • ACR Convergence 2024

    EspANDE Project: Improvement of Primary Care-Rheumatology Coordination in Spondyloarthritis in a Health Area in Northern Spain

    Julio Sánchez-Martín1, Cristina Martinez-Dubois2, Javier Rueda Gotor3, Gabriel Pinedo-Lopez2, Alvaro Perez-Martin2, Roberto Gonzalez-Santamaria2, Belén Atienza-Mateo4, Vanesa Calvo-Rio5, Inigo Gonzalez-Mazon6, Natalia Palmou Fontana4, Enriqueta Peiro-Callizo2, Diana Prieto-Peña4, Lara Sanchez Bilbao7, Fernando Lopez-Gutierrez8 and Ricardo Blanco-Alonso9, 1Hospital Universitario 12 de Octubre, Madrid, Spain, 2Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, 3Hospital Sierrallana, Torrelavega, Cantabria, Spain, 4Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, 5Valdecilla Hospital, Santander, Cantabria, Spain, 6H. U. Marques de Valdecilla, Santander, Cantabria, Spain, 7Rheumatology and Ophthalmology. Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, 8Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, 9Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: Spondyloarthritis (SpA) constitutes a diverse set of inflammatory rheumatic diseases with a prevalence of 1.9% in the general population. Diagnostic delay, identified as a…
  • Abstract Number: 0558 • ACR Convergence 2024

    Patient Diagnostic Journey and Time to Diagnosis in Axial Spondyloarthritis: A Retrospective Cohort Study Using US Claims Data

    Maureen Dubreuil1, Marina Magrey2, Kathrin Haeffs3, Evgueni Ivanov4 and Julie Gandrup Horan5, 1Section of Rheumatology, Boston University School of Medicine, Boston, MA, 2Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH, 3UCB Pharma, Monheim, Germany, 4UCB Pharma, Bulle, Switzerland, 5UCB Pharma, Slough, United Kingdom

    Background/Purpose: The journey to axial spondyloarthritis (axSpA) diagnosis is often prolonged and challenging, resulting in poor clinical, psychological, social, and economic outcomes.1 Understanding the factors…
  • Abstract Number: 0557 • ACR Convergence 2024

    What Factors Are Associated with Pain Intensity in Axial Spondyloarthritis? Results from the International Map of Axial Spondyloarthritis (IMAS)

    Marco Garrido-Cumbrera1, Victoria Navarro Compán2, Fernando Andres Sommerfleck3, Christine Bundy4, Souzi Makri5, José Correa-Fernández6, Shashank Akerkar7, Jo Lowe8, Elie Karam9 and Denis Poddubnyy10, 1Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain / Spanish Federation of Spondyloarthritis Patient Associations (CEADE), Madrid, Spain, Seville, Spain, 2La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, 3Sanatorio Julio Mendez, Buenos Aires, Argentina, 4Cardiff University, Cardiff, UK, Cardiff, United Kingdom, 5Cyprus League for People with Rheumatism (CYLPER), Nicosia, Cyprus, Nicosia, Cyprus, 6Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, Seville, Spain, 7Mumbai Arthritis Clinic, Mumbai, India, Mumbai, India, 8Axial Spondyloarthritis International Federation, London, United Kingdom, 9Canadian Spondylitis Association (CSA), Toronto, Canada, Toronto, Canada, 10Charite-Universitatsmedizin Berlin, Berlin, Germany

    Background/Purpose: Severe pain in patients with axial spondyloarthritis (axSpA) can cause deterioration in their physical and mental health. The aim is to investigate factors associated…
  • Abstract Number: 0550 • ACR Convergence 2024

    Is the Diagnostic Delay Getting Shorter with Time for Patients with Spondyloarthritis? Data from the International ASAS-PerSpA Study

    Nelly Ziade1, Ihsane Hmamouchi2, Clementina López Medina3, Maroun Aoun4, Sherif Gamal5, Maxime Dougados6 and Bassel Elzorkany7, and ASAS-PerSpA, 1Saint-Joseph University, Beirut, Lebanon, 2International University of Rabat, Rabat, Morocco, 3Reina Sofia University Hospital, Cordoba, Spain, 4Saint Joseph University, Beirut, Lebanon, 5Cairo University, Cairo, Egypt, 6Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, 7Private (BZRC), Cairo, Egypt

    Background/Purpose: Although diagnostic tools and management of spondyloarthritis (SpA) have recently improved, data on their impact on diagnostic delay (DD) are still conflicting. In this…
  • Abstract Number: 0542 • ACR Convergence 2024

    Impact of Peripheral Arthritis on Disease Activity Outcomes in Patients with Axial Spondyloarthritis, Peripheral Spondyloarthritis and Psoriatic Arthritis. Data from the ASAS-PerSpA Study

    Clementina López Medina1, Sofia Ramiro2, Dafne Capelusnik3 and Anna Molto4, 1Reina Sofia University Hospital, Cordoba, Spain, 2Leiden University Medical Center, Bunde, Netherlands, 3Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, 4Groupe Hospitalier Cochin, AP-HP, Paris, France

    Background/Purpose: Patients with spondyloarthritis (SpA) can present with several phenotypes (i.e., axial SpA (axSpA), peripheral SpA (pSpA) and Psoriatic Arthritis (PsA)) and peripheral arthritis can…
  • Abstract Number: 0504 • ACR Convergence 2024

    Janus Kinase Inhibitors Persist Longer Than Biologics in Rheumatoid Arthritis: Retrospective Analysis of Real-world Outpatient Data from the German Rhadar Database

    Linus Maximilian Risser1, Torsten Witte2, Matthias Englbrecht3, Patrick-Pascal Strunz4, Matthias Froehlich5, Marc Schmalzing6, Michael Gernert7, Peter Bartz-Bazzanella8, Cay von Der Decken9, Kirsten Karberg10, Georg Gauler11, Susanna Spaethling-Mestekemper12, Christoph Kuhn13, Wolfgang Vorbrueggen14, Martin Welcker15 and Stefan Kleinert16, 1Hannover Medical School, Hannover, Germany, 2Dept of Immunology and Rheumatology, Hannover, Germany, 3Freelance Healthcare Data Scientist, Eckental, 4University hospital of Wuerzburg, Wuerzburg, Germany, 5Uniklinikum Wuerzburg, Medizinische Klinik II, Wuerzburg, Germany, 6University Hospital Wuerzburg, Würzburg, Germany, 7Medicine II, Division Rheumatology/Clinical Immunology, University Hospital of Wuerzburg, Wuerzburg, 8Rhein-Maas Klinikum, Wuerselen, Germany, 9Klinik für Internistische Rheumatologie, Rhein-Maas-Klinik Wuerselen, Würselen, 10Rheumatologisches Versorgungszentrum Steglitz, Berlin, Germany, 11rheumapraxis, Osnabrück, Germany, 12Rheumapraxis Muenchen, Muenchen, Germany, 13Praxis für Rheumatologie, Karlsruhe, Germany, 14Verein zur Foerderung der Rheumatologie e.V, Wuerselen, Germany, 15Medizinisches Versorgungszentrum für Rheumatologie Dr. M. Welcker GmbH, Planegg, Germany, 16Praxisgemeinschaft Rheumatologie - Nephrologie (PGRN), Erlangen, Germany

    Background/Purpose: Numerous biologic and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) have been approved for treating rheumatoid arthritis (RA), including Janus kinase inhibitors (JAKi), rituximab, abatacept,…
  • Abstract Number: 0503 • ACR Convergence 2024

    Use of Janus Kinase Inhibitors Before and After European Medicines Agency Safety Recommendations

    Patrick-Pascal Strunz1, Linus Maximilian Risser2, Matthias Englbrecht3, Torsten Witte4, Matthias Froehlich5, Marc Schmalzing6, Michael Gernert7, Peter Bartz-Bazzanella8, Sebastian Hueper9, Cay von Der Decken10, Georg Gauler11, Susanna Spaethling-Mestekemper12, Christoph Kuhn13, Kirsten Karberg14, Wolfgang Vorbrueggen15, Martin Welcker16 and Stefan Kleinert17, 1University hospital of Wuerzburg, Wuerzburg, Germany, 2Hannover Medical School, Hannover, Germany, 3Freelance Healthcare Data Scientist, Eckental, 4Dept of Immunology and Rheumatology, Hannover, Germany, 5Uniklinikum Wuerzburg, Medizinische Klinik II, Wuerzburg, Germany, 6University Hospital Wuerzburg, Würzburg, Germany, 7Medicine II, Division Rheumatology/Clinical Immunology, University Hospital of Wuerzburg, Wuerzburg, 8Rhein-Maas Klinikum, Wuerselen, Germany, 9Praxis für Rheumatologie und Osteologie, Hildesheim, Germany, 10Klinik für Internistische Rheumatologie, Rhein-Maas-Klinik Wuerselen, Würselen, 11rheumapraxis, Osnabrück, Germany, 12Rheumapraxis Muenchen, Muenchen, Germany, 13Praxis für Rheumatologie, Karlsruhe, Germany, 14Rheumatologisches Versorgungszentrum Steglitz, Berlin, Germany, 15RheumaDatenRhePort GbR, Wuerselen, Germany, 16Medizinisches Versorgungszentrum für Rheumatologie Dr. M. Welcker GmbH, Planegg, Germany, 17Praxisgemeinschaft Rheumatologie - Nephrologie (PGRN), Erlangen, Germany

    Background/Purpose: Safety recommendations for Janus kinase inhibitors (JAKi) issued by the European Medical Agency (EMA) in 2023 could potentially influence prescription patterns for drugs used…
  • Abstract Number: 0575 • ACR Convergence 2024

    Combined Testing of anti-CD74 IgA and Anti-UH-axSpA Antibodies Increases the Diagnostic Potential for axSpA

    Kurt de Vlam1, Pieter Ruytinx2, Elien luyten2, Anouk Agten2, Frank Vandenabeele2 and Veerle somers2, 1Department of Rheumatology, UZ Leuven, and Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium, 2Universiteit Hasselt, Hasselt, Belgium

    Background/Purpose: Diagnosis of axial spondyloarthritis (axSpA) is challenging and a specific laboratory diagnostic test is lacking. Previously, we identified novel immunoglobulin G (IgG) and IgA…
  • Abstract Number: 0394 • ACR Convergence 2024

    Unveiling Major Challenges and Unmet Needs in the Therapeutic Approach to Systemic Juvenile Idiopathic Arthritis: The Patient Perspective

    Francesco Baldo1, Luciana Peixoto2, Remco Erkens3, Greta Rogani3, Claudia Bracaglia4, Dirk Foell5, Marco Gattorno6, Marija Jelusic7, Sebastiaan Vastert3, Rashmi Sinha2 and Francesca Minoia8, and on behalf of the PReS MAS/sJIA Working Party and the Systemic JIA Foundation, 1Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, 2Systemic JIA Foundation, Cincinnati, OH, 3University Medical Center Utrecht, Utrecht, Netherlands, 4IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, 5University Hospital Muenster, Muenster, Germany, 6IRCCS Giannina Gaslini, Genoa, Italy, 7University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Zagreb, Croatia, 8Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Milan, Italy

    Background/Purpose: Despite continuous improvements in the therapeutic options for children with systemic juvenile idiopathic arthritis (sJIA), access to medications significantly differs among centres and countries.…
  • Abstract Number: 0549 • ACR Convergence 2024

    Global Distribution and Determinants of Diagnostic Delay Across Diverse Spondyloarthritis Entities: Data from the International ASAS-Perspa Study

    Nelly Ziade1, Sherif Gamal2, Maroun Aoun3, Ihsane Hmamouchi4, Clementina López Medina5, Maxime Dougados6 and Bassel Elzorkany7, and ASAS-PerSpA, 1Saint-Joseph University, Beirut, Lebanon, 2Cairo University, Cairo, Egypt, 3Saint Joseph University, Beirut, Lebanon, 4Rheumatology Unit, Lalla Aicha Temara Hospital, Temara, Rabat, Morocco, 5Reina Sofia University Hospital, Cordoba, Spain, 6Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, 7Private (BZRC), Cairo, Egypt

    Background/Purpose: Diagnostic delay (DD) in spondyloarthritis (SpA) is well documented, but most of the available data are reported in patients with axial SpA (axSpA). In…
  • Abstract Number: 0537 • ACR Convergence 2024

    Evaluating the Usage of Janus Kinase Inhibitors in Rheumatology and Its Impact on Cardiovascular Risk

    Knkush Hakobyan1, Talar Acob2, Mesrop Aleksanyan3, Tigran Kakhktsyan3, Omar Jumaah3 and Sajina Prabhakaran4, 1Capital Health medical center, Princeton, NJ, 2College of medicine-university of Baghdad, Plainsboro Township, NJ, 3Capital Health Medical Center, Trenton, 4Capital health Rheumatology specialists, Newtown, PA

    Background/Purpose: Janus kinase (JAK) inhibitors have been widely used in treatingrheumatological conditions like rheumatoid arthritis and psoriatic arthritis. Despite theirefficacy, there are concerns regarding major…
  • Abstract Number: 0411 • ACR Convergence 2024

    Axial Radiographic Structural Damage in Enthesitis-Related Arthritis in Children and Young Adult Patients

    Annelyse de Araújo Pereira1, Marcelo Pinheiro2, Jade Dib Fernandez1, Ana Sakamoto3, Adham do Amaral e Castro1 and Maria Teresa Terreri4, 1UNIFESP-EPM, São Paulo, SP, Brazil, 2UNIFESP/ EPM, São Paulo, SP, Brazil, 3Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil, 4UNIFESP, São Paulo, SP, Brazil

    Background/Purpose: Enthesitis-related arthritis (ERA), a distinct subtype of juvenile idiopathic arthritis (JIA) related to HLA-B27 status and peripheral and axial involvement, presents with insidious onset…
  • « Previous Page
  • 1
  • …
  • 350
  • 351
  • 352
  • 353
  • 354
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology